No description available.

1,4-Dihydropyridines (DHPs) are a classification of compounds used as calcium channel blockers in the treatment of various conditions. These compounds readily undergo photodegradation. The degradants produced have no pharmaceutical activity and render the drugs ineffective. DHPs also exhibit polymorphism. Nifedipine and Nimodipine are two such drugs. This study aimed to monitor the photodegradation of these two drugs and to establish the effect of particle size, polymorphism and β-Cyclodextrin (β-CD) on the rate of photodegradation. Different polymorphs (namely the amorphous and stable crystalline polymorphs) of the two drugs were prepared for use in the study. Mixtures of each drug with β-CD were also prepared for photostability studies. The mixtures were prepared in a 1:1 molar ratio. The rate of photodegradation was studied with a 500 W metal halide lamp in accordance to ICH guidelines. The study employed samples on a small scale where degradation was analysed with High Performance Liquid Chromatography, and also samples on a larger scale where degradation was monitored with Powder X-ray Diffraction. The two sets of results of observing the degradation process by two analytical techniques where compared in terms of their quantification methods. The extent of photodegradation was suitably modelled and fitted using the Avrami-Erofeyev kinetic equation. Smaller particle size showed increased photodegradation for Nimodipine; the effect was insignificant for Nifedipine however. For both drugs it was found that the amorphous polymorph underwent faster photodegradation. The study showed that β-CD caused an increase in photodegradation for both drugs under these experimental conditions.

No description available.

Thesis (M.D)--Dept. of Clinical and Experimental Pharmacology, University of Adelaide, 1993. / Includes 4 published papers by the author as part of appendix 9. Includes bibliographical references (leaves 1-19 (second sequence)).

Nifedipine, in a 5mg sublingual acute administration, causes a significant fall in the systolic, diastolic and mean arterial pressure in a mixed group of pregnant hypertensives. A concurrent, significant rise in the pulse rate was seen. The utero-placental blood flow index, which is a measure of utero-placental blood flow, was not significantly reduced following the administration of Nifedipine or a placebo. The utero-placental blood flow index was found to be a consistent measure of utero-placental blood flow in resting patients. In the absence of serious side-effects it can be concluded that Nifedipine is a safe therapy in the acute treatment of hypertensive states in pregnancy.

No description available.

No description available.

Made available in DSpace on 2014-06-11T19:28:03Z (GMT). No. of bitstreams: 0 Previous issue date: 2002-02-25Bitstream added on 2014-06-13T18:32:31Z : No. of bitstreams: 1 sousa_cp_me_arafo.pdf: 282394 bytes, checksum: da271e59dd6d66efadb106512dc6504c (MD5) / O objetivo deste trabalho foi avaliar a prevalência e severidade do crescimento gengival em pacientes brasileiros sob terapia com nifedipina, por meio do uso do Novo Índice Clínico para Crescimento Gengival Induzido por Drogas(Índice DIGO). O estudo foi realizado em 35 pacientes sob terapia com nifedipina (grupo teste ) e em um grupo controle de 35 pacientes. Foram feitos os registros das variáveis demográficas (idade e sexo do paciente), farmacológicas (dose e tempo de uso da nifedipina) e das variáveis periodontais (índice de placa, índice gengival, profundidade de sondagem, nível de inserção clínico, sangramento à sondagem) e do crescimento gengival. O teste Z (nível de significância a 5% e p<0.05) e a correlação de Spearman foram usados para a comparação dos resultados entre os grupos teste e controle. Os resultados mostraram que o crescimento gengival foi observado em 68% dos pacientes e que não houve associação entre o crescimento gengival e as variáveis demográficas e as variáveis farmacológicas. No entanto, houve associação entre o crescimento gengival e as variáveis periodontais, exceto para o índice de placa. Podemos concluir que a inflamação gengival apresentou influência no crescimento gengival associado à nifedipina. / The aim of this study was to evaluate the occurrence of nifedipine induced GO in patients and the risk factors associated using a New Clinical Index for Drug Induced Gingival Overgrowth (DIGO) and the relation between The study was carried out with 35 patients under treatment with nifedipine (test group) and 35 patients without treatment (control group). There was assessed the characteristics of demographic (age, gender), pharmacological (dose, time of use), periodontal variables (plaque index, gingival index, probing depth, attachment level, bleeding on probing) and gingival overgrowth of the sample. The test Z (significance level at 5% - p< 0.05) and the Spearman correlation were used to compare data in test and control groups. Gingival overgrowth was noticed in 68% of patients. The statistical analyses showed no association between the gingival overgrowth and demographic and pharmacological variables, except for the plaque index. However, there was an association between the gingival overgrowth and periodontal variables. Further, it is possible to conclude that the presence of gingival inflammation was the main factor of risk to promote nifedipine-induced gingival overgrowth.

Nifedipine is a photolabile calcium channel antagonist which undergoes rapid photodegradation in solution and in solid-state with an accompanying loss of pharmacological potency and clinical efficacy. Nifedipine photostabilization which has received considerable attention has principally been achieved by physical obscuration and through the use of colourants or ultraviolet light absorbers incorporated into liquid preparations, translucent packaging materials, gelatin capsules and/or their fillings and tablet coatings or cores. This study was initiated by a South African pharmaceutical manufacturer in response to increasing evidence that cyclodextrin (CD) inclusion complexation may improve drug photostability. The brief was to evaluate the potential of selected cyclodextrins as photoprotecting agents for nifedipine in the solid-state. Areas of investigation included i) quantitative method development and validation for selective determination of nifedipine, ii) phase solubility studies to establish the solubilizing potential and complexing tendencies of selected cyclodextrins, iii) preparation of solid-state nifedipine - cyclodextrin binary systems using an industrially applicable method, iv) pre-formulation photostability studies to determine the effects of the cyclodextrins on solid-state nifedipine photostability and v) comparative in vitro dissolution assessments of nifedipine, the nifedipine - cyclodextrin binary systems and their respective physical mixtures. Phase solubility studies demonstrated that soluble nifedipine - cyclodextrin complexes were formed in aqueous solution, but the magnitude of the interactions were generally low as reflected by the calculated stability constants which decreased in the rank order, heptakis (2,6-dimethyI)-β-CD (DM-β-CD) > randomly methylated-β-CD (RM-β-CD) > β-CD ≈ 2-hydroxypropyl-β-CD (2HP-β- CD) > γ-CD ≥ 2-hydroxypropyl-γ-CD (2HP-γ-CD). An industrially applicable kneading method yielded binary systems with spectral and thermal characteristics similar to the respective physical mixtures, implying weak solid-state inclusion complexation. Preparation of an amorphous nifedipine - RM-β-CD product using a heating method is reported. A 1.7- and 1.9-fold improvement in solid-state nifedipine photostability was observed for I : 1 molar ratio β-CD and γ-CD kneaded products, respectively, when exposed to window-filtered daylight and could be attributed to changes in opacity of the crystalline kneaded products. The remaining cyclodextrins produced negligible nifedipine photostabilization. Nifedipine in vitro dissolution was improved considerably from γ-CD and RM-β-CD .kneaded products as a result of increased nifedipine wettability, solubility and reduced particle size. iii

A venlafaxina é um fármaco usado no tratamento da depressão e dos transtornos de ansiedade generalizada. É disponível na clínica na forma de mistura racêmica dos enantiômeros S-(+) e R-(-) em formulação de liberação controlada. O enantiômero S-(+) inibe a recaptação da serotonina, enquanto o enantiômero R-(-) inibe a recaptação da serotonina e da norepinefrina. A venlafaxina é biotransformada pelo CYP2D6 e CYP2C19 em seu principal metabólito, O-desmetilvenlafaxina, o qual apresenta atividade farmacológica semelhante à venlafaxina. Outros metabólitos da venlafaxina, dependentes do CYP3A4, incluem a N-desmetilvenlafaxina e a N,O-di-desmetilvenlafaxina. A absorção e a distribuição da venlafaxina são moduladas pela ação da glicoproteina-P. O nifedipino, um fármaco da classe dos inibidores dos canais de cálcio, é descrito como inibidor da glicoproteina-P. O presente estudo investiga a influência do nifedipino na disposição cinética e no metabolismo da venlafaxina em voluntários sadios caracterizados como portadores de atividade normal do CYP3A (omeprazol como fármaco marcador) e fenotipados como metabolizadores rápidos do CYP2C19 (omeprazol como fármaco marcador) e do CYP2D6 (metoprolol como fármaco marcador). Os voluntários investigados receberam, em estudo cruzado e randomizado, dose única oral de 150 mg de venlafaxina racêmica (Fase 1) e 40 mg de nifedipino associada com dose única oral de 150 mg de venlafaxina racêmica (Fase 2). Foram coletadas amostras seriadas de sangue até 72 horas após a administração dos fármacos para o estudo farmacocinético. As concentrações plasmáticas dos enantiômeros da venlafaxina e de seus metabólitos foram determinadas por LC-MS/MS utilizando a coluna Chirobiotic V com fase móvel constituída de mistura de metanol: solução aquosa de acetato de amônio 15 mmol/L pH 6,0 (80:20, v/v). A farmacocinética da venlafaxina mostrou-se enantiosseletiva com acúmulo plasmático (AUC 526,0 vs 195,7 ng.h/mL) e menores valores de clearance (Cl/f 142,67 vs 408,01 L/h) para o enantiômero S-(+). A disposição cinética do metabólito ativo O-desmetilvenlafaxina apresentou enantiosseletividade apenas no parâmetro concentração plasmática máxima com observação de maiores valores para o enantiômero R-(-) (Cmax 69,33 vs 56,94 ng/mL). A disposição cinética da N,O-di-desmetilvenlafaxina também mostrou-se enantiosseletiva apenas para o parâmetro concentração plasmática máxima, mas com observação de maiores valores para o enantiômero S-(+) (Cmax 7,08 vs 4,61 ng/mL). A administração de dose única oral de 40 mg de nifedipino não alterou a farmacocinética de ambos os enantiômeros da venlafaxina e de seus metabólitos O-desmetilvenlafaxina e N,O-di-desmetilvenlafaxina, seja utilizando teste estatístico não paramétrico (teste de Wilcoxon para dados pareados, p < 0,05), seja avaliando o IC 90% das razões das médias geométricas de AUC e Cmax (Fase 2/Fase 1). Os dados obtidos evidenciam que o nifedipino na dose de 40 mg não age como um inibidor da P-gp / Venlafaxine is a drug used to treat depression and generalized anxiety disorders. It is available in clinical practice in the form of a racemic mixture of S-(+) and R-(-) enantiomers, in controlled release formulation. The S-(+) enantiomer inhibits the reuptake of serotonin, while the R-(-) enantiomer inhibits the reuptake of both serotonin and norepinephrine. Venlafaxine is biotransformed by CYP2D6 and CYP2C19 in its major metabolite, O-desmethylvenlafaxine, which has similar pharmacological activity when compared to venlafaxine. Other metabolites of venlafaxine, dependent of CYP3A4, include N-desmethylvenlafaxine and N, O-di-desmethylvenlafaxine. The absorption and distribution of venlafaxine are modulated by the action of P-glycoprotein. Nifedipine, a calcium channel blocker drug, is described as an inhibitor of P-glycoprotein. The present study investigates the influence of nifedipine on the kinetic disposition of venlafaxine enantiomers and its metabolites in healthy volunteers characterized as having normal activity of CYP3A (omeprazole as a probe drug) and phenotyped as rapid metabolizers of CYP2C19 (omeprazole as a probe drug) and CYP2D6 (metoprolol as a probe drug). The enrolled volunteers received, in a randomized, two-way study, a single 150 mg oral dose of racemic venlafaxine (Phase 1) and 40 mg oral dose of nifedipine associated with a single 150 mg oral dose of racemic venlafaxine (Phase 2). Serial blood samples were collected until 72 hours after drug administration to the pharmacokinetic study. Plasma concentrations of venlafaxine enantiomers and its metabolites were determined by LC-MS/MS using a Chirobiotic V column and a mobile phase constituted of methanol: aqueous 15 mmol/L ammonium acetate solution pH 6.0 (80:20, v/v). The venlafaxine pharmacokinetics is enantioselective with plasma accumulation (AUC 526.0 vs 195.7 ng h/mL) and lower clearance values (CL/f 142.67 vs 408.01 L/h) for the S-(+) enantiomer. The kinetic disposition of the active metabolite O-desmethylvenlafaxine exhibits enantioselectivity only in the maximum plasma concentration parameter with higher values for the R-(-) enantiomer (Cmax 69.33 vs 56.94 ng/mL). The kinetic disposition of N,O-di-desmethylvenlafaxine is also enantioselective only for the maximum plasma concentration parameter, but with higher values for the S-(+) enantiomer (Cmax 7.08 vs 4.61 ng/ml). Administration of a 40 mg single oral dose of nifedipine do not alter the pharmacokinetics of both enantiomers of venlafaxine and its metabolites O-desmethylvenlafaxine and N,O-di-desmethylvenlafaxine, using non-parametric statistical test (Wilcoxon test for paired data, p <0.05), or evaluating the 90% CI of the AUC and Cmax geometric mean ratios (Phase 2/Phase 1). The obtained data show that nifedipine in a 40 mg oral dose does not act as a P-gp inhibitor.